Us Anti Coagulant Therapy Market Outlook, 2025- Sample

Report Code :HC 1335
United States Anticoagulation Therapy Market Outlook
2025: Opportunity & Growth Analysis, 2017-2025
+1-646-568-7747
+1-437-886-1181
+44-203-318-6627
+91-120-473-0422, +91-991-
071-6331
sales@goldsteinresearch.
com
www.goldsteinresearch.com
99 Wall Street, Suite No:- 527,
New York, NY 10005
United States of America
Office No:- 504, 5th Floor, C-51,
BSI Business Park,
Sector-62, Noida, PIN:- 201301
United States
Published By: Goldstein Research
Copyright All Rights Reserved, Goldstein Research www.goldsteinresearch.comCopyright All Rights Reserved, Goldstein Research www.goldsteinresearch.com
United States Anticoagulation Therapy Market
Outlook

Table OF Contents
Connect With Us:
Outlook

Copyright All Rights Reserved, Goldstein Research www.goldsteinresearch.com
Vision Value Visibility
Chapter 1: Research Methodology
1.1. Secondary Research
1.2. Primary Research
1.3. Data Analyzing & Market Size Estimation
1.4. Research Design
1.5. Bottom-Up & Top-Down Approach
Chapter 2: United States Anticoagulation Therapy Market Outlook, 2017-2025
2.1. United States Anticoagulation Therapy Market Environment
2.2. Market Size (USD Billion), 2017-2025
2.3. Forecast Analysis (2017-2025)
2.4. Market Share & CAGR (%)
2.5. Medicare & Medicaid: Healthcare Expenditure Outlook
2.6. Demographic & Economic Patterns
2.7. US Healthcare Indicators
2.8. National Health Expenditure
2.9. Competitive Strategies
2.10. Research & Development Investments
2.11. Marketing & Distribution Strategy
2.13. Manufacturing Outlook
2.14. Merger & Acquisitions Activities
2.15. Demand & Supply Outlook
2.16. Value Chain Analysis
2.17. Reimbursement Scenario In US
2.18.Urgent Care Clinics Market Outlook
Chapter 3: Market Dynamics
3.1. Growth Drivers
3.2. Market Restraints
3.3. Risk Analysis (Supply & Demand)
3.4. Economic Variations
3.5. Recent Trends & Developments
3.6. Opportunities

Chapter 4: United States Anticoagulation Therapy Market Segmentation
4.1. On The Basis of Product Type
4.1.1. United States Anticoagulation Drug Market Analysis, 2017-2025
4.1.1.1. US Novel Anticoagulants Market Analysis, 2017-2025
➢ Market Size (USD Billion), CAGR (%) & YoY Growth Analysis
➢ Current & Future Trends
➢ Generic & Branded Drug Market Outlook
➢ Market Size & Market Share Analysis, By NOACs Drug Types
➢ Market Share Analysis, By Players
➢ Pipeline Products
➢ Sales & Production Data Outlook
➢ Supply & Demand Outlook
4.1.1.2. US Warfarin (VKA) Market Analysis , 2017-2025
➢ Generic & Branded Drug Market Outlook
➢ Market Share Analysis, By NOACs Drug Types
4.1.1.3. Other Anticoagulant Drugs Market Analysis
4.1.2. United States PT/INR Testing Devices Market Analysis, 2017-2025
4.1.2.1. US In-office Testing Devices Market Analysis
➢ Market Share Analysis, By In-Office Testing Device Types
➢ Market Share Analysis, By Brands

4.1.2.2. US Analyzers Market Analysis
➢ Market Share Analysis, By Analyzers Types
4.1.2.3. US Anticoagulant Reagent & Kits Market Analysis
➢ Market Share Analysis, By Types
4.1.2.4. US Anticoagulation Home Testing Devices Market Analysis
➢ Market Share Analysis, By Types
4.1.3. United States Anticoagulant Therapy Service Market Analysis, 2017-2025
4.1.3.1. US Anticoagulation Therapy Testing Service Market Analysis
➢ Market Share Analysis, By Service Types
4.1.3.2. US Anticoagulation Therapy Consulting Service Market Analysis
➢ Market Share Analysis, By Service Types

4.2. End Users Analysis
4.2.1. Hospital Associated Clinic Market Analysis, 2017-2025
✓ Market Size (USD Mn) & CAGR, 2017-2025
✓ Year on Year Growth Rate (%), 2017-2025
4.2.2. Independent Clinic Market Analysis, 2017-2025
4.2.3. Pharmacy Based Clinic Market Analysis, 2017-2025
4.2.5. BPS Analysis and Market Attractiveness, 2017-2025
Chapter 5: Competitive Outlook
▪ Market Share of Major Players (2017)
▪ Company Profiles
▪ Abbott
▪Company Synopsis
▪Business Strategy
▪Product Portfolio
▪SWOT Analysis
▪ C. H. Boehringer Sohn
▪ Bristol-Myers Squibb
▪ Johnson & Johnson
▪ Pfizer
▪ Daiichi Sankyo
▪ Portola Pharmaceuticals
▪ Roche
▪ Siemens
▪ CoaguSense
▪ Others Global & Regional Players

Chapter 6: Porter’s Five Force Model & PESTEL Analysis
Chapter 7: Market Landscape: Competition and Beyond
Chapter 8: Market outlook for business players and entry level players to ascertain
their business in dynamic ecosystem
Chapter 9: Expert Analysis
Chapter 10: Concluding Remarks

Research methodology
Connect With Us:
Outlook

Goldstein Research follows a comprehensive and rigorous research
methodology to provide you accurate estimates and forecast of a
particular market. We provide estimates, forecast and analysis primarily
based on secondary research, primary interviews, in-house database and
other free as well paid sources.
Our company follows simultaneous top down and bottom approach in
order to provide you the accurate market sizing. Data triangulation
method is strictly followed where we triangulate the data from all the
aspects, be it Function Type, application, industry verticals, material,
product type or geography.
In addition, the research methodology we follow is a systematic approach
in order to estimate and project the market sizing keeping in mind all the
on-going and upcoming trends of the market. We conduct both primary
and secondary research in order to estimate a market and validate our key
findings.
We put together our effort and prepare an inclusive questionnaire
depending on the title of the market we are tracking and extract the
important information we require to validate our findings. Our team of
Analysts and experts dedicatedly put their effort to provide you the best
possible and accurate data and analysis. Adding to that; technological,
economic, cultural and social aspects along with the regulatory barriers are
completely analysed to understand the comprehensive market scenario
across different geographies.
Understanding the market from both buyer and seller point of view is
important to track a market and provide analysis on the same. We not only
provide the market data of the four geographies as a whole, namely, North
America, Europe, Asia-Pacific, Latin America, Middle East & Africa and Rest
of United States (RoW) but we also provide you qualitative as well we
qualitative information on country level bifurcation.
We at Goldstein Research provide you:
• Precise Estimates and Forecast
• Authentic Analysis
• In-depth Data and Analysis
• Authentic Sources
• Reliable Data and Analysis
ResearchMethodology
Research Methodology

Executive Summary
Connect With Us:
Outlook

XX%
XX%
XX%
Hospital Associated Clinic Independent Clinics Pharmacy-based Clinics
XX XX XX XX XX XX XX XX XX
XX%
XX%
XX% XX%
XX% XX% XX% XX% XX%
XX%
XX%
XX%
XX%
XX%
XX%
XX%
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
2017e 2018e 2019f 2020f 2021f 2022f 2023f 2024f 2025f
Source: Goldstein Research
In 2017, Drugs accounted for the market share
XX%in United States Anticoagulation Therapy
Market
United States Anticoagulation Therapy market is
growing at XX%Y-O-Y and XX% CAGR
Source: Goldstein ResearchSource: Goldstein Research
Outlook
United States Anticoagulation Therapy
Market Share (%), By End-Users, 2017
US Anticoagulation Therapy Market
Share (%), By Product Type, 2017
United States Anticoagulation Therapy Market Size USD (Billion). 2017-2025
XX%
XX%
XX%
Drugs PT/INR Testing Devices Services
XX%
CAGR: (2017-2025)

XX
XX
XX
XX XX XX XX
XX
XX
XX
XX
XX XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
Xarelto Eliquis Pradaxa Savaysa Bevyxxa Warfarin Plavix Others
2017 2025
Outlook
United States Anticoagulation Drugs Market Size USD (Billion), By Drug Type, 2017-2025
Cases 2016 2017 2018
Stroke XX Million XX Million XX Million
Heart Attack XX Million XX Million XX Million
Pulmonary Embolism XX Million XX Million XX Million
Number of Thromboembolic Events (Millions) in United States, 2016-2018
United States Anticoagulation PT/INR Testing Devices Market Size USD (Billion), By
Device Category, 2017-2025
XX
XX
XX XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
In-Office Testing
Devices
Analyzers Reagents and Kits Home Testing Devices
2017 2025

Outlook
United States Anticoagulation Drugs Data Statistics, 2017
Drugs Total
Reimbursement
Prescription
Count
Average
Prescription Cost
Generics Market
(USD Bn)
Xarelto
(rivaroxaban)
USD XX XX Million USD XX USD XX Bn
Pradaxa
(dabigatran
etexilate)
Eliquis (apixaban) USD XX XX Million USD XX USD XX Bn
Warfarin (generic
Coumadin)
Clopidogrel
(generic Plavix)
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
2017e 2018e 2019f 2020f 2021f 2022f 2023f 2024f 2025f
Branded Generic
United States Anticoagulation Drugs Market Size USD (Billion), By Drug Category, 2017-
2025

Outlook
United States Anticoagulation Therapy Market Share Analysis, 2017
XX%
XX%
XX%
XX%
XX%XX%
10.0%
18.0%
10.0%
3.0%2.0%
Janssen Pharmaceuticals
Boehringer Ingelheim
Bristol Myers Squibb
Pfizer
Daiichi Sankyo
Portola Pharmaceuticals
Roche
Abbott
Siemens
CoaguSense
Others
United States Anticoagulation Therapy Market Share & Size, By Product Category
Product Category
Xarelto
Eliquis
Pradaxa
Savaysa
Bevyxxa
XX XX XX XX XX XX XX XX
2017e 2018e 2019f 2020f 2021f 2022f 2023f 2025f
2017e 2018e 2019f 2020f 2021f 2022f 2023f 2025f
2017e 2018e 2019f 2020f 2021f 2022f 2023f 2025f
2017e 2018e 2019f 2020f 2021f 2022f 2023f 2025f
2017e 2018e 2019f 2020f 2021f 2022f 2023f 2025f
XX%
XX%
XX%
XX%
XX%
Market Size (USD Billion), 2017-2025 Market Share (%), 2017
CAGR: XX%
CAGR: XX%
CAGR: XX%
CAGR: XX%

Outlook
United States Anticoagulation Therapy Market Share & Size, By Product Category
Product Category
Warfarin
Plavix
In-Office Testing Devices
Analyzers
Reagents and Kits
Home Testing Devices
Testing Services
Consulting Services
2017e 2018e 2019f 2020f 2021f 2022f 2023f 2025f
2017e 2018e 2019f 2020f 2021f 2022f 2023f 2025f
2017e 2018e 2019f 2020f 2021f 2022f 2023f 2025f
2017e 2018e 2019f 2020f 2021f 2022f 2023f 2025f
2017e 2018e 2019f 2020f 2021f 2022f 2023f 2025f
2017e 2018e 2019f 2020f 2021f 2022f 2023f 2025f
2017e 2018e 2019f 2020f 2021f 2022f 2023f 2025f
2017e 2018e 2019f 2020f 2021f 2022f 2023f 2025f
XX%
XX%
XX%
XX%
XX%
XX%
XX%
XX%
Market Size (USD Billion), 2017-2025 Market Share (%), 2017
CAGR: XX%
CAGR: XX%
CAGR: XX%
CAGR: XX%

United States Anticoagulation Therapy Market Size (USD Billion), By Cities,
2017-2025
2017
2025
New York Los Angeles
USD XX Billion
USD XX Billion USD XX Billion
USD XX Billion
▪ United States Anticoagulation Therapy market was worth USD XX billion in 2017 and
is expected to hit about USD XX billion by 2025. This increase in market is attributed
to the increased demand of promising and novel diagnostics technologies, increased
numbers of geriatric population and increasing awareness among the population
regarding the early diagnosis of life threatening diseases.
▪ Novel oral anticoagulant (NOACs) is the top performing segment as an alternative to
anticoagulant. Increasing number of patients with lifelong medical aid therapy,
growing prevalence of blood vessel thromboembolism, arrhythmia, and stroke,
acceptance of NOAC’s is raising revenue in the market, rising outpatient
anticoagulation therapy, increasing number of pipeline products under clinical trials
and rising heparin trade spurring the growth of anticoagulation therapy market.
However, high cost of developing drugs and risk of malfunctions like increased
bleeding is main issue with newer agents are expected to impact the target market
negatively.
▪ Presently, the NOACs segment is a major revenue-generating segment in the
anticoagulants market and is anticipated to show dominance during the forecast
period, owing to growing adoption of NOACs in developing countries and rising use of
NOACs over the warfarin. Presently, NOACs drugs, such as rivaroxaban, betrixaban,
apixaban, edoxaban, and dabigatran, are available in the market. Furthermore,
NOACs offer various advantages over the warfarin, such as rapid onset action, lesser
interaction with drugs and food, predictable pharmacokinetic action, shorter half-life,
and no dietary restriction. These have been further supporting the market growth. On
the other side, lack of antidote for NOACs and higher price impede the anticoagulants
industry growth.
▪ Presently, the atrial fibrillation & heart attack segment is a major revenue contributor
and is anticipated to show dominance throughout the forecast period, owing to large
target population and increased use of anticoagulants in treatment of these
conditions. However, DVT is expected to witness fastest market growth, owing
to increased prevalence of DVT and technological advancement in diagnosis of DVT.
Outlook
Growing IT
Healthcare
Rise in
bleeding
population
Rising
inpatients
Rising
Diagnostic
Laboratories
Advancement
in In-Vitro
Diagnostics

United States Anticoagulation Therapy
Market Analysis, 2017-2025
Connect With Us:
Outlook

United States NOAC's Market Size (USD
Billion) & Growth Analysis
United States NOAC's Market Size (USD Billion)-2017-2025
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
2017 2018 2019 2020 2021 2022 2023 2024 2025
✓United States Novel Oral Anticoagulant Market is anticipated to expand
at a compound annual growth rate of XX% during the forecast period i.e. 2017-2025. The most
commonly prescribed anticoagulant is Warfarin. Newer types of anticoagulants are also available
and are becoming increasingly common. These include rivaroxaban (Xarelto), dabigatran (Pradaxa),
apixaban (Eliquis), and edoxaban (Savaysa/Lixiana). Warfarin and the newer alternatives are taken
as tablets or capsules. There's also an anticoagulant called heparin that can be given by injection.
The global anticoagulants market is supported by various growth drivers such as growing aging
population, rising prevalence of coagulant disorders, increasing demand for NOACs, rising
awareness about anticoagulants, etc. Yet, the market faces some challenges which are obstructing
the growth of the market. Some of the challenges are stringent regulations from regulatory bodies,
high cost of oral anticoagulants, major side-effects associated with the drugs, etc.
✓Bayer, BMS/Pfizer, Boehringher Ingelheim and Daiichi Sankyo are some of the key players
operating in the global anticoagulants market, whose company profiling has been done in the
report.
XX%
CAGR: (2017-2025)

Market Players Data Analysis, By Product
United States Anticoagulation Therapy Market Share (%) , By Companies & Product Category, 2017 &
2025
Product Category Total Value (USD BN),2017 Total Value (USD BN),2025
Market Share Analysis of
Players
Drugs
Xarelto
XX XX ABC (%), XYZ (%), etc.
Eliquis
Pradaxa
Savaysa
Bevyxxa
Warfarin
Plavix
PT/INR Testing Devices
In-Office Testing Devices
Analyzers
Reagents and Kits
Home Testing Devices
Services
Testing Services
Consulting Services

Regional and Market Players Data Analysis
United States Anticoagulation Therapy Ranking , By Companies, 2018
Ranking Regional & International Players Total Revenue (USD BN),2018
1. ABC XX
2. ABC XX
3. ABC XX
4. ABC XX
5. ABC XX
6. ABC XX
7. ABC XX
8. ABC XX
9. ABC XX
10. ABC XX
11. ABC XX
12. ABC XX
13. ABC XX
14. ABC XX
15. ABC XX
16. ABC XX
17. ABC XX
18. ABC XX
19. ABC XX
20. ABC XX
21. ABC XX
22. ABC XX
23. ABC XX

Market Dynamics
Connect With Us:
Outlook

Moderately Complex
Faulty
regulations
leading to
disorientation
of In-vitro
Diagnostics.
Lack of
Laboratories
with proper
accreditation
Lack of
awarenes
s
General Trend
Emerging Markets
Highly Complex Waived
Instant
Therapy
Result
Confidenti
ality
Ancillary
Services
Market Dynamics
Growth Drivers Growth Barriers
Sample

Growth Drivers
Connect With Us:
Outlook

Anticoagulant Costs to Medicare and Medicaid: Reimbursements
Among anticoagulants, Medicaid reimbursements have increased the most for Xarelto, a factor Xa
inhibitor that accounted for $1.5 million in Medicaid reimbursement in the District of Columbia in
2016. This amount was more than seven times higher than the total Medicaid reimbursement for
Eliquis, which had the second highest Medicaid reimbursement for anticoagulants ($202,896). In 2016,
Xarelto had a higher total Medicaid prescription count than warfarin (4,174 vs. 3,402), an effective,
established generic drug that had the second highest number of Medicaid prescriptions. This is an
important point in DC Medicaid drug utilization, because prescriptions for an expensive branded drug
have overtaken an inexpensive, generically available medication. In terms of prescription count in
2016, the generic form of Plavix, clopidogrel, had the largest number of total Medicaid prescriptions.
Medicare claims costs for Eliquis were the highest among all anticoagulants at $3.3 million. Xarelto had
the next highest total Medicare claims cost with $3.0 million, followed by Pradaxa with $1.1 million.
Clopidogrel had the highest number of Medicare claims among anticoagulants in 2016, with 17,318
claims; warfarin had 10,893 claims.
High Medium Low
Impact on United States
Anticoagulation Therapy
Market
Impact Analysis:-
▪ Government funding for the advancement
in healthcare sector and initiatives to
promote healthcare across the globe is
expected to positively impact on the
growth of medical service market.
▪ Increase in aging population and
unfocused lifestyle tends to drive the
anticoagulant market
Growth Drivers
XX
XX
XX
0 50 100 150 200 250 300 350 400
2000
2025
2050
US Population Aged 80yrs & over (Millions)
Source: XXX
Population(Million) Aged 80 yrs. & over, US-2000-2050

The ongoing arrival of anticoagulant reversal agents (for example, Boehringer Ingelheim’s Praxbind
[idarucizumab] and upcoming Portola Pharmaceuticals’ AndexXa [andexanet alfa]) that could be
employed in the case of a serious bleeding event, are poised to give NOAC developers an additional
marketing boost
➢ In 2017, NOACs continue to dominate the anticoagulant landscape, but there are promising pipeline
agents that are being developed. Ionis and Bayer are developing IONIS-FXIRX, a second-generation
antisense anticoagulant drug in Phase II clinical trials that separates antithrombotic activity from
bleeding risk. It is expected IONIS-FXIRX to launch in 2022. There is also tecarfarin, a novel vitamin K
antagonist in Phase III clinical trials for patients with prosthetic heart valves and renal insufficiency. It is
expected tecarfarin, being developed by Espero and Armetheon, to launch in 2023.
➢ Major growth in the anticoagulant market continued through 2017, primarily due to the increasing global
prevalence of multiple cardiovascular (CV) indications including atrial fibrillation, acute coronary
syndrome, peripheral artery disease and venous thromboembolism. However, cheap and established
anticoagulants such as warfarin and heparin continue to present a barrier for new anticoagulant
entrants.
➢ After the launch of the novel oral anticoagulants (NOACs) almost a decade ago, encouraging NOAC
clinical trial data along with increased experience managing patients taking NOACs, has led physicians to
acknowledge that the drugs offer several benefits. Advantages include the fact that they do not require
regular monitoring and are known to be safer and non-inferior – if not superior – in efficacy to the
historical anticoagulants (warfarin and heparin). All of the aforementioned attributes have led to the
enormous success of these agents.
➢ Despite the first marketed NOAC, Boehringer Ingelheim’s Pradaxa (dabigatran), soon facing generic
erosion, the NOACs – specifically, direct factor Xa inhibitors (Xarelto [rivaroxaban], Eliquis [apixaban],
Lixiana/Savaysa [edoxaban], and Bevyxxa [betrixaban]) – will dominate the CV market for years. Historical
and projected sales for branded NOACs, specifically direct factor Xa inhibitors, can be seen in the figure
below, with Bayer and Johnson & Johnson’s Xarelto and Bristol-Myers Squibb and Pfizer’s Eliquis leading
in overall global sales.
Market Drivers
Figure: Historical And Projected Global Sales Of Branded Noacs, Direct Factor Xa Inhibitors ($M)

Market Restraints
Connect With Us:
Growth Drivers
Outlook

Fierce competition from manufacturers from the US, the UK, and Japan
➢ The rural population of United States is 66.86 % in 2017, whereas rest population are living in urban areas, who are unaware
of the advanced medical facilities and unable to access the treatment for several diseases. Lack of awareness towards
medical devices & treatments in rural regions is hindering the growth of syringes market at a large scale
➢ Due to unavailability of medical services & facilities in many under developed regions, hence deprived the population to
experience the treatment facilities with sophisticated technology based medical devices
➢ Absence of convenience of healthcare facilities & less disposable income in rural regions across the globe are restraining the
demand for syringes market.
➢ Population living below poverty line across the globe are deprived from home healthcare facilities and unable to opt
expensive services for treatments & cure
High Medium Low
Impact on United States
Anticoagulation Therapy Market
Impact Analysis:-
▪ The population living in rural areas across US
are unable to get clinical treatments with
medical devices due to less disposable income
are some of the factors which is restraining the
growth of healthcare market.
▪ Many states are underdeveloped and viewing
low economies . These regions are unable to
embrace advanced healthcare facilities which is
curbing the growth of healthcare industry.
Market Restraints
Bleeding & Urban Population (%)- United States , 2017
66.86%
33.14%
• XX% of the total population of United States
population is lived at or below USD 1.90 per
day in the year 2012
• In United States , XX% of people are
undernourished
• Rural population is growing at a rate of XX%
and urban population is growing at a rate of
XX%
• XX% of old age and XX% of young age
population is dependent on working-age
population
Sample

Market Demand and
Supply Risk
Connect With Us:
Outlook

Risk Analysis
Market Demand Risk-Low
On the basis of
Cost-effectiveness
On the basis of Aging
Population
The demand for In-vitro Diagnostics
is likely to grow due to availability
of cost-effective products for
cardiac diseases in developing &
under-developed countries like
Africa , United States , etc. Rising
demand for In-vitro Diagnostics
benefits the new players to get into
the market to provide affordable
products and provide opportunities
for expansion of business by
existing players in the In-vitro
Diagnostics market.
Rise in aging population coupled
with higher risk of chronic diseases
and rising prevalence of diabetes
and cardiovascular diseases in
elderly population further raise the
demand by adopting cost-effective
and advanced cardiac devices &
services in the upcoming years. The
rise in demand will help the new
players to enter into the sector of
cardiology and open the doors for
the expansion of business.
Rising awareness towards fitness &
changing lifestyles for the
betterment of health are some of
the factors swelling the demand for
cardiac devices & services. Rapid
growth in urbanization leads to
hectic and busy schedules which
leads to adopt time saving
treatment. The high demand from
the consumers is expected to make
easy for new players to jump into
the market of cardiology devices.
On the basis of Rising concerns
towards healthcare
Sample
Market Supply Risk-Low
On the basis of Technological
Advancements
On the basis of Governmental
Regulations
On the basis of Investment
Due to rise in advancement in
healthcare technology by
government funding in order to
provide portable and high-end
devices with better services
and to improve care as wells as
treatment technology which is
expected to raise the supply.
Presence of strict government
regulations across the globe for
the manufacturing of In-vitro
Diagnostics to provide safe and
secure products with less side-
effects to the consumers. This is
expected to be a huge restrain
for the new players.
The initial cost to setup cardiac
device industry is very high due
to requirement of research and
development sector and high
accuracy and precise healthcare
manufacturing equipment with
expertise which is expected to
put many limitations.
Sample

Connect With Us:
Market Opportunity
Outlook

Fig: 19: Impact of Latest Trends on In-Vitro Diagnostics
Market
Opportunity, 2017-2025
Technology Innovation
Medical technologies also allow
healthcare Diagnostics companies on
their toes for a few years now. At the
same time, it pushed them to expand
and find opportunities in this shift in
customer trends. Offering In-Vitro
Diagnostics by the hour was one of the
first resolutions that the leading In-Vitro
Diagnostics companies implemented.
which resulted in taking a share of the
new demand.
Car-sharing is a recent phenomenon in
developing countries, only taking root
within the last three years. Although
there are few car-sharing operators in
developing countries, the number of
systems is growing. Car-sharing is most
active in Central and South United
States , which has five systems in
operation, and in Turkey, with three
small systems. Following those two
areas, United States currently has two
car-sharing operators, while Zoom will
mark the first car-sharing operation
in United States
The green vehicle
Shifting the focus to green vehicles will
not only give a more economical
alternative to customers, but will
contribute to a bigger cause –
increasing awareness about pollution
and the negative effects it has on the
environment.
For some In-Vitro Diagnostics
companies, this step might be as an
alternative to higher oil prices, and for
others/
Trends And Opportunities
United States economic recovery played a significant
role in the performance of the travel industry. United
States GDP growth went from XX per cent in 2017 to XX
per cent in 2017. Consequently that lead to an increase
in the disposable income for travellers, especially in
developing countries.
We can certainly argue that the increase in the buying
power of consumers, combined with low-cost airfares in
the airline industry, directly influenced the growth in the
In-Vitro Diagnostics market. Still In-Vitro Diagnostics
companies cannot rely only on United States economic
growth for future success.
There are few more aspects that will have a disruptive
effect on the In-Vitro Diagnostics industry. Some of them
bringing opportunities and some of them representing
challenges.
Impact
Analysis (on
the basis of
Latest Trends
Fleet
Management
XX%
Government
Initiative
XX%
Usage-Based
Insurance
XX%
Real-time
information
XX%
Data-
enabled Car
management
XX%

Attractiveness and BPS Analysis by Product Type, 2017-
2025
Fig: 17: United States Anticoagulation Therapy Market Attractiveness-By Product Type, 2017-
2025
Subscription segment holds the largest revenue share in United States Anticoagulation Therapy market as
this segment constitutes which is impacted by the rising cognizance among the household users and thus it
is likely to expand at XX% CAGR during the forecast period.
In-Vitro Diagnostics market is relying on the adoption of EHR (Electronic health record) software by various
healthcare facility providers in order to stand ahead in future. Behavioral health EHR creates a United
States of difference to the staff and patients and goes the extra mile giving advanced capabilities such as
it include support for documenting violence risk factors, suicide risk factors, or sadness scales.
Fig: 17: United States Anticoagulation Therapy Market BPS Analysis- By Modality, 2017-2025
Immunochemistry Clinical Chemistry
XX% XX%
XX% XX%
XX% XX%
XX% XX%
XX% XX%
XX% XX%
XX% XX%
XX% XX%
XX%
XX%
XX%
XX%
XX%
XX%
XX%
2016 2024
Others
Biochemistry
Molecular Diagnostics
Clinical Microbiology
Coagulation & Hemostasis
Hematology
Clinical Chemistry
Immunochemistry
0%
5%
10%
15%
20%
25%
0 10 20 30 40 50 60 70 80 90 100
Market Size (USD Billion)
CAGR(%)
Hematology Coagulation and Hemostasis
Clinical Microbiology Molecular Diagnostics Biochemistry Others
Sample

Company Profiling
Outlook
Outlook : 2017-2025
Connect With Us:

Abbott
Connect With Us:

Abbott (Company Overview & Business Strategy)
Founded
1888
Employees
94,000
Headquarters
U.S.
Website
www.abbott.com
Major Products
Health and Dietary supplements
Starlims (Integrated Solutions)
Blood Glucose Monitoring Systems
I-Stat Systems
Chemistry Analyzers
Business Strategy
Acquisition and Investment Strategy: The company is focusing towards the expansion of its product
portfolio by acquiring pharmaceutical companies such as St. Jude, Alere Inc, Tendyne Holdings Inc.,
Veropharm, CFR Pharmaceuticals S.A, Topera, Inc., and many more. Aforementioned acquisitions have
resulted in a wide range of outcomes, from successful introduction of new products and technologies. In
2017 and 2015 Abbott management approved the plans to update operations in order to reduce cost and
improve overall efficiency in various Abbott business segments include nutritional and vascular business
segments. Abbott is long established as a leader in diagnostics, nutrition and medicines. Company’s
acquisition of St. Jude Medical makes it a premier In-vitro Diagnostics company, as well. Today Abbott
offer a leading portfolio of innovative solutions in diabetes, cardiovascular, and neuromodulation.
Company Overview
▪ Abbott Laboratories, is an American multinational
company engaged in development and manufacturing
of health care products.
▪ The Company operates through three geographic
segments: Americas; Europe and Asia Pacific region.
▪ Abbott Laboratories is traded on NYSE stock exchange,
America
▪ The company also provides generic pharmaceuticals,
medical devices and nutrition products.
▪ Abbott Point-of-Care manufactures diagnostic devices
for blood analysis, that provides health care
professionals diagnostic information at the point of
patient care.
▪ Abbott also provides cloud services to manage system
infrastructure without additional hardware purchase
and software installation.

XX
XX
XX
2014 2015 2016
Revenue(USDBillion)
Abbott(Revenue & Financial Analysis)
Business Strategy
Improves quality control structure and United States ization: The company has adopted various methods
to enhance their manufacturing structure which helps the company to improve the quality of their
automobile products. Moreover, the company is looking forward towards expansion of United States
ization. Abbott Motors adopted Hertz Corporation United States Vision in 2011 to improve the
quantitative expansion across the globe. The company is investing a huge amount for research and
development activities to introduce the future of material handling equipment such as hydrogen powered
forklifts and automated guided vehicles. The company spend USD 588.11 Million in 2017 for research and
development of their products and services. Hertz Corporation motors is one of the largest automobile
and mental health software across the globe and expected to lead other United States companies in near
future.
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
2014 2015 2016
Fig: 9-2 Material Handling Equipment Sales (Thousand Units),
2014-2017
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
2014 2015 2016
Fig: 9-3 Hertz Corporation Corporation
Revenue (USD Billion), 2014-2017

Abbott (Business Segments & Recent News)
Business Strategy
Improves quality control structure and United States ization: The company has adopted various methods
to enhance their manufacturing structure which helps the company to improve the quality of their
automobile products. Moreover, the company is looking forward towards expansion of United States
ization. Abbott Motors adopted Hertz Corporation United States Vision in 2011 to improve the
quantitative expansion across the globe. The company is investing a huge amount for research and
development activities to introduce the future of material handling equipment such as hydrogen powered
forklifts and automated guided vehicles. The company spend USD 588.11 Million in 2017 for research and
development of their products and services. Hertz Corporation motors is one of the largest automobile
and mental health software across the globe and expected to lead other United States companies in near
future.
Fig :- 9-4 Abbott Revenue (%)-By Business
Segments, 2017
XX%
XX%
XX%
Automo
tive
Materia
l
Handlin
g
Other
Fig :- 9-5 Abbott Revenue (%), By Region,
2017
XX%
XX%
XX%
XX%
XX%
Japan
North-
America
Europe
Asia
Other
Key Findings
▪ Hertz Corporation Corporation (TICO) has signed an agreement to acquire Vanderlande – United States
market leader for value-added logistic process automation at airports and in the parcel market, as well as
being a leading supplier for warehouses – from the company’s current owner NPM Capital
▪ Hertz Corporation Corporation announces that it has concluded an agreement with major North American
materials handling systems integrator Bastian Solutions LLC (“Bastian”) to acquire the company. The
acquisition of Bastian signify Hertz Corporation' full-scale entry into the North American materials handling
solutions industry amid the e-commerce boom.
▪ To expand company’s presence in emerging countries, Hertz Corporation acquired the lift truck business of
Taiwan-based Tailift Co., Ltd. In August 2015. By capitalizing on Tailift’s strength, company aimed to increase
its sales in emerging c9oountries where market expansion is expected over the medium to long term.

Abbott : Business Strategy
Environmental
Scan
Assessment
Background
Information
Situational
Analysis
SWOT–
Strength’s,
Weaknesses,
Opportunities,
Threats
Situation–Past,
Presentand
Future
SignificantIssues
Align/Fitwith
Capabilities
Mission&Vision
Values/Guiding
Principles
KeyObjectives
Performance
Measurement
Targets/Standards
ofPerformance
Initiativesand
Projects
BaselineComponents
Performance
Management
ReviewProgress–
Balanced
Scorecard
TakeCorrective
Actions
Downto
Specifics
Evaluate
Whereweare
GapsActionPlansFeedback
upstream–revise
plans
WherewewanttobeHowwewilldoitHowarewedoing

Expert Analysis
United States Anticoagulation Therapy Industry Outlook
Connect With Us:

▪ In 2017, medical consumables dominated the market; immunochemistry segment
accounted for nearly XX% of the total Asia-Pacific & Africa point of care testing (POCT)
devices market and remaining XX% went for different end-use segments such as
homecare settings. The main reason for this despaired share is due to the rising
demand for point of care testing devices in In-Vitro Diagnostics on the back of their
advantages such as faster and precise results
▪ However, as the medical device technology is on rise (especially in developing
countries), the Africa therapeutic market is projected to reach USD XXXX million in 2023
from USD XXXX million in 2017, registering a growth rate of XX%. In addition to that,
Africa pharmaceutical market touched USD XXXX million in 2017 and rising demand for
prescription medicines in the region is expected to accelerate the market to USD XXXX
million by the end of 2023
▪ As a result, if seen from the big market point of view, blood glucose monitoring devices
demand is higher in homecare settings followed by In-Vitro Diagnostics . Moreover, the
rising healthcare expenditure in Africa on the back of new healthcare reforms and rising
investment in healthcare sector is expected to bolster the growth of point of care
testing devices in Africa & Asia-Pacific region
▪ With USD XXXX million in 2017, blood glucose monitoring devices has the highest
demand followed by located hemoglobin (HbA1c) testing devices and blood collection
devices. The advancement in diagnostic devices are encouraging the hospitals and In-
Vitro Diagnostics to adopt the advanced devices to obtain accurate diagnosis data. The
precise data would further help the physicians to provide better treatment to the
patients
▪ Further, increasing spending by government authorities on research and development
of innovative and advanced medical devices along with rising disease burden are some
of the major reasons behind the spiked growth of Asia-Pacific & Africa point of care
testing (POCT) devices market
▪ Further, increasing spending by government authorities on research and development
of innovative and advance connected devices along with rising disease burden are
some of the major reasons behind the spiked growth of Middle East & Africa In-Vitro
Diagnostics market.
Expert Analysis
Business Strategy

About Us
Outlook
Connect With Us:

About Us
Based in U.S., Goldstein Research is a young business consulting and
market research firm with vast reach across America, Asia and parts of Europe
and the Middle East. In the next five years, we strive to expand our reach to
50+ nations spanning across Europe, Asia and parts of the Middle East and
Africa. We strive to realize a strong brand presence United States ly through
our quality research and forecasting solutions. With 30+ domain experts and
50+ employees working day and night to crunch numbers and bring out the
best and detailed market reports and forecasts, we strive to enable you to
foresee upcoming market challenges and develop a robust business model and
strategies, which would add to your profitability and market visibility as a
brand.
Our mission is simple: to develop insightful business solutions, help our
clients make powerful future decisions to keep them well ahead of the game
which is the market, and leave a mark across businesses and communities
through our well-defined ideas and clear cut forecasts.
Our mission is simple: to develop insightful business solutions, help our clients
make powerful future decisions to keep them well ahead of the game which is
the market, and leave a mark across businesses and communities through our
well-defined ideas and clear cut forecasts.

Terms of Use
Kindly note that the publications made by Goldstein Research are
exclusively proprietary. The market information revealed is subjected to
the approval with an appropriate e-mail requested to Goldstein Research.
Initial data and content can be published with a written permission of
Goldstein Research. Further, to be noted that no part of our strategic
business quantitative or qualitative data or analysis should be used for
general purpose. It’s a non -disclosure and not for public disclosure.
Accuracy of the data are solely contingent to the primary interview
conducted and it may result in mare variations. So, we do not take
responsibility; however the data and the information provided are at our
utmost precision.
Kindly note: Any lending, disclosure, resale, or copying of this
publication can only be prepared with preceding written approval from
Goldstein Research.
Photocopying, mechanical, electronic, recording or otherwise are strictly
prohibited deprived of permission from Goldstein Research. Also,
transmission of this document by any means or in any form are still
strictly forbidden.

Contact Us: For Research & Sales Related Queries
www.goldsteinresearch.com
99 Wall Street, Suite No:-
527, New York, NY 10005
United States of America
Office No:- 504, 5th
Floor, C-51, BSI Business
Park, Sector-62, Noida,
PIN:- 201301
United States
+1-646-568-7747
+1-437-886-1181
+44-203-318-6627
+91-120-473-0422
+91-991-071-6331
sales@goldsteinresearch.com
Corporate Office:

Thank you
Outlook
Connect With Us:

Us Anti Coagulant Therapy Market Outlook, 2025- Sample

Recommended

Recommended

More Related Content

What's hot

What's hot (14)

Similar to Us Anti Coagulant Therapy Market Outlook, 2025- Sample

Similar to Us Anti Coagulant Therapy Market Outlook, 2025- Sample (20)

More from Goldstein Market Intelligence

More from Goldstein Market Intelligence (20)

Recently uploaded

Recently uploaded (20)

Us Anti Coagulant Therapy Market Outlook, 2025- Sample